Stay updated with breaking news from Arrowhead Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report released on Monday, Benzinga reports. They currently have a $90.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2028 earnings at $0.43 EPS. A number of other equities analysts […]
Global Alpha-1 Antitrypsin Deficiency Industry is expected to reach US$ 10 Billion by registering a CAGR of 12.8% by 2033
Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.
The global Alpha-1 Antitrypsin Deficiency market is poised to achieve a market value of US$3 billion in 2023, with projections indicating a remarkable growth to US$10 billion by 2033, driven by a substantial CAGR of 12.8% during the forecast period. The surge in respiratory illnesses plays a pivotal role in expandin...
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Analyst Ratings This is a breakdown of current […]